Andrew Oberst

Andrew Oberst

Auto-generated profile, based on publicly available information

Andrew Oberst

University of Washington

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 June 2019 in Science Immunology
Verified
Journal Article
Closed access
PDF file
ASAnnelise G. Snyder
Annelise G. Snyder
NHNicholas W. Hubbard
Nicholas W. Hubbard
MMMichelle N. Messmer
Michelle N. Messmer
SKSigal B. Kofman
Sigal B. Kofman
CHCassidy E. Hagan
Cassidy E. Hagan
AOAndrew Oberst
Andrew Oberst
Although the signaling events that induce different forms of programmed cell death are well defined, the subsequent immune responses to dying cells in the context of cancer remain relatively unexplored. Necroptosis occurs downstream of the receptor-interacting protein kinases RIPK1 and RIPK3, whose activation leads to lytic cell death accompanied by de novo production of proinflammatory mediators. Here, we show that ectopic introduction of necroptotic cells to the tumor microenvironment promotes BATF3+ cDC1− and CD8+ leukocyte–dependent antitumor immunity accompanied by increased tumor antigen loading by tumor-associated antigen-presenting cells. Furthermore, we report the development of constitutively active forms of the necroptosis-inducing enzyme RIPK3 and show that delivery of a gene encoding this enzyme to tumor cells using adeno-associated viruses induces tumor cell necroptosis, which synergizes with immune checkpoint blockade to promote durable tumor clearance. These findings support a role for RIPK1/RIPK3 activation as a beneficial proximal target in the initiation of tumor immunity. Considering that successful tumor immunotherapy regimens will require the rational application of multiple treatment modalities, we propose that maximizing the immunogenicity of dying cells within the tumor microenvironment through specific activation of the necroptotic pathway represents a beneficial treatment approach that may warrant further clinical development.

1 January 2019 in Immunity
Verified
Journal Article
Closed access
BDBrian P. Daniels
Brian P. Daniels
SKSigal B. Kofman
Sigal B. Kofman
JSJulian R. Smith
Julian R. Smith
GNGeoffrey T. Norris
Geoffrey T. Norris
ASAnnelise G. Snyder
Annelise G. Snyder
AOAndrew Oberst
Andrew Oberst

6 June 2014 in Cell Death & Differentiation
Verified
Journal Article
Closed access
SOS Orozco
S Orozco
NYN Yatim
N Yatim
MWM R Werner
M R Werner
HTH Tran
H Tran
SGS Y Gunja
S Y Gunja
AOA Oberst
A Oberst

1 March 2017 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
KGKimberley D. Gutierrez
Kimberley D. Gutierrez
MDMichael A Davis
Michael A Davis
BDBrian P. Daniels
Brian P. Daniels
TOTayla M. Olsen
Tayla M. Olsen
PRPooja Ralli-Jain
Pooja Ralli-Jain
AOAndrew Oberst
Andrew Oberst
Necroptosis is a form of programmed cell death defined by activation of the kinase receptor interacting protein kinase 3 and its downstream effector, the pseudokinase mixed lineage kinase domain-like (MLKL). Activated MLKL translocates to the cell membrane and disrupts it, leading to loss of cellular ion homeostasis. In this study, we use a system in which this event can be specifically triggered by a small-molecule ligand to show that MLKL activation is sufficient to induce the processing and release of bioactive IL-1β. MLKL activation triggers potassium efflux and assembly of the NLRP3 inflammasome, which is required for the processing and activity of IL-1β released during necroptosis. Notably, MLKL activation also causes cell membrane disruption, which allows efficient release of IL-1β independently of the recently described pyroptotic effector gasdermin-D. Taken together, our findings indicate that MLKL is an endogenous activator of the NLRP3 inflammasome, and that MLKL activation provides a mechanism for concurrent processing and release of IL-1β independently of gasdermin-D.

20 July 2022 in Nature
Verified
Journal Article
Closed access
PDF file
NHNicholas W. Hubbard
Nicholas W. Hubbard
JAJoshua M. Ames
Joshua M. Ames
MMMegan Maurano
Megan Maurano
LCLan H. Chu
Lan H. Chu
KSKim Y. Somfleth
Kim Y. Somfleth
AOAndrew Oberst
Andrew Oberst

1 April 2017 in Cell
Verified
Journal Article
Closed access
BDBrian P. Daniels
Brian P. Daniels
ASAnnelise G. Snyder
Annelise G. Snyder
TOTayla M. Olsen
Tayla M. Olsen
SOSusana Orozco
Susana Orozco
TOThomas H. Oguin
Thomas H. Oguin
AOAndrew Oberst
Andrew Oberst